All In Biotech

Drug Trial Radar · NCT00095823

A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Aripiprazole as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder.

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,200

Actual

Start

Jun 2004

Primary completion

Aug 2006

Study completion Aug 2006

Sponsor

Sponsor type
Industry
Collaborators
Otsuka America Pharmaceutical
First posted
Nov 9, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patients with Major Depressive Disorder.

Conditions

  • Major Depressive Disorder

Interventions

  • Antidepressant + PlaceboDrug

    Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.

  • Antidepressant + AripiprazoleDrug

    Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in a depression rating scale at endpoint

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Local Institution

    Garden Grove, California

  • Local Institution

    Northridge, California

  • Local Institution

    Washington D.C., District of Columbia

  • Local Institution

    Jacksonville, Florida

  • Local Institution

    Chicago, Illinois

  • Local Institution

    Edwardsville, Illinois

  • Local Institution

    Rockville, Maryland

  • Local Institution

    Springfield, Massachusetts

  • Local Institution

    Farmington Hills, Michigan

  • Local Institution

    Okemos, Michigan

  • Local Institution

    Staten Island, New York

  • Local Institution

    Portland, Oregon

  • Local Institution

    Philadelphia, Pennsylvania

  • Local Institution

    Austin, Texas

  • Local Institution

    Salt Lake City, Utah

  • Local Institution

    Woodstock, Vermont

  • Local Institution

    Charlottesville, Virginia

  • Local Institution

    Bellevue, Washington

  • Local Institution

    Seattle, Washington

  • Local Institution

    Middleton, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.